Literature DB >> 10971127

The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen.

K Nirei1, M Kaneko, M Moriyama, Y Arakawa.   

Abstract

Hepatitis B virus (HBV) DNA has been detected in the sera of hepatitis patients who are negative for hepatitis B surface antigen (HBsAg) by polymerase chain reaction (PCR). The purpose of the present study was to clarify the clinical characteristics of patients with chronic hepatitis C who are negative for serum HBsAg and positive for HBV DNA. The subjects included 49 patients with chronic hepatitis C who were negative for serum HBsAg and 119 blood donors who served as healthy controls. Serum samples were tested for the presence of HBV DNA by the nested PCR method. Serum HBV DNA was detected in 18 (37.7%) of the 49 chronic hepatitis C patients and in none (0%) of the 119 blood donors. Among the hepatitis C patients, HBV DNA was detected in 20.7% of those who were negative for all HBV-associated markers and in 57.1% of those who were positive for one or more HBV-associated marker. The HBV DNA-positive rate among those in each F stage did not significantly differ. The liver function parameters of the HBV DNA-positive and the HBV DNA-negative chronic hepatitis C patients did not significantly differ. These results suggest that hepatitis C virus is frequently coinfected with serum HBsAg-negative HBV, and that the incidence of HBV infection in blood donors is low. However, it is considered that HBsAg-negative HBV infection does not modify the blood biochemical features of chronic hepatitis C. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971127     DOI: 10.1159/000025030

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  6 in total

Review 1.  Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes.

Authors:  Conrado M Fernandez-Rodriguez; Maria Luisa Gutierrez; José Luis Lledó; Maria Luisa Casas
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

2.  Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.

Authors:  Mohamed H Emara; Nahla E El-Gammal; Lamiaa A Mohamed; Maged M Bahgat
Journal:  Virol J       Date:  2010-11-17       Impact factor: 4.099

3.  Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone.

Authors:  Debika Bhattacharya; Chi-Hong Tseng; Janet P Tate; Vincent Lo Re; Cynthia L Gibert; Adeel A Butt; Sheldon T Brown; Joseph K Lim; Maria C Rodriguez-Barradas; David Rimland; Erica Kaufman; Amy C Justice; Matthew Bidwell Goetz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-05-01       Impact factor: 3.731

4.  Occult HBV infection among Egyptian hepatocellular carcinoma patients.

Authors:  Zeinab K Hassan; Mohamed M Hafez; Tarek M Mansor; Abdel Rahman N Zekri
Journal:  Virol J       Date:  2011-03-03       Impact factor: 4.099

5.  Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.

Authors:  Mohamed H Emara; Mohamed I Radwan
Journal:  Virol J       Date:  2011-11-14       Impact factor: 4.099

6.  Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection.

Authors:  Kazushige Nirei; Tatsuo Kanda; Hitomi Nakamura; Shunichi Matsuoka; Tadatoshi Takayama; Masahiko Sugitani; Mitsuhiko Moriyama
Journal:  Int J Med Sci       Date:  2018-03-08       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.